Skip to content
Global Blood Therapeutics Commitment to Sickle-Cell Innovation episode artwork

May 22, 2023 22 min

Global Blood Therapeutics Commitment to Sickle-Cell Innovation

from Pathfinders in Biopharma

In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specific challenges the company faced in tackling a rare orphan disease. GBT was acquired by Pfizer in October 2022, reinforcing their commitment to sick cell disease and continuing to build on their 30-year legacy in the rare hematology space.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Global Blood Therapeutics Commitment to Sickle-Cell Innovation

0:00 22:29

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Pathfinders in Biopharma?

This episode is 22 minutes long.

When was this Pathfinders in Biopharma episode published?

This episode was published on May 22, 2023.

Can I download this Pathfinders in Biopharma episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.